RARA CRAFT DATABASE for FDA Medical Devices
510(k)K182001

FDA DEVICE FACTS

Acucy Influenza A&B Test with the Acucy System

SEKISUI Diagnostics, LLC

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEDecember 17, 2018PRODUCT CODEPSZ

Indications for use

Locations Clinical laboratories and Point of Care (POC) sites Same Calibrator Yes – QC verification cassette provided Yes – Calibration cassette and QC card provided Storage Temperature Room temperature Same Test Internal Control Internal procedure control Same Reader Quality Control Features · Scanning procedural control zone for adequate flow · Reader prevents use of used cassettes · Reader prevents use of expired cassettes · Prevents improper cassette insertion Same External Controls · Influenza A Positive/B Negative Control · Influenza B Positive/A Negative Control · Positive Influenza A/Influenza B Control · Negative Control User · CLIA moderate complexity laboratory technologist. · Users in CLIA waived settings, such as nurses and medical assistants at emergency rooms, urgent care clinics, and outpatient clinics, including physician’s offices. Same

K. Standard/Guidance Document Referenced (if applicable): · Food and Drug Administration, 21 CFR 866.8328: Microbiology Devices; Reclassification of Influenza Virus Antigen Detection Test Systems Intended for Use Directly with Clinical Specimens, Final Order, January 12, 2017 · Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses, July 15, 2011 · Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices, January 30, 2008 · Select Updates for Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices, Draft Guidance, November 29, 2017 · Recommendations for Dual 510(k) and CLIA Waiver by Application Studies, Draft Guidance, November 29, 2017 · Administrative Procedures for CLIA Categorization, Guidance for Industry and Food and Drug Administration Staff, October 2, 2017 · FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, May 11, 2005 · General Principles of Software Validation, Final Guidance for Industry and FDA Staff, January 11, 2002 · Content of Premarket Submissions for Management of Cybersecurity in Medical Devices, Guidance for Industry and FDA Staff, October 2, 2014

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 26, 2026